Mycobacterium ulcerans disease in the middle belt of Ghana: An eight-year review from six endemic districts.
Identifieur interne : 000944 ( PubMed/Curation ); précédent : 000943; suivant : 000945Mycobacterium ulcerans disease in the middle belt of Ghana: An eight-year review from six endemic districts.
Auteurs : Emmanuel J K. Adu [Ghana] ; Edwin Ampadu [Ghana]Source :
- International journal of mycobacteriology [ 2212-554X ] ; 2015.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Antibactériens (administration et posologie), Enfant, Femelle, Ghana (épidémiologie), Humains, Jeune adulte, Maladies endémiques, Mycobacterium ulcerans (), Mycobacterium ulcerans (génétique), Mycobacterium ulcerans (isolement et purification), Mycobacterium ulcerans (physiologie), Mâle, Rifampicine (administration et posologie), Streptomycine (administration et posologie), Ulcère de Buruli (microbiologie), Ulcère de Buruli (traitement médicamenteux), Ulcère de Buruli (épidémiologie).
- MESH :
- administration et posologie : Antibactériens, Rifampicine, Streptomycine.
- génétique : Mycobacterium ulcerans.
- isolement et purification : Mycobacterium ulcerans.
- microbiologie : Ulcère de Buruli.
- physiologie : Mycobacterium ulcerans.
- traitement médicamenteux : Ulcère de Buruli.
- épidémiologie : Ghana, Ulcère de Buruli.
- Adolescent, Adulte, Enfant, Femelle, Humains, Jeune adulte, Maladies endémiques, Mycobacterium ulcerans, Mâle.
English descriptors
- KwdEn :
- Adolescent, Adult, Anti-Bacterial Agents (administration & dosage), Buruli Ulcer (drug therapy), Buruli Ulcer (epidemiology), Buruli Ulcer (microbiology), Child, Endemic Diseases, Female, Ghana (epidemiology), Humans, Male, Mycobacterium ulcerans (drug effects), Mycobacterium ulcerans (genetics), Mycobacterium ulcerans (isolation & purification), Mycobacterium ulcerans (physiology), Rifampin (administration & dosage), Streptomycin (administration & dosage), Young Adult.
- MESH :
- chemical , administration & dosage : Anti-Bacterial Agents, Rifampin, Streptomycin.
- drug effects : Mycobacterium ulcerans.
- drug therapy : Buruli Ulcer.
- epidemiology : Buruli Ulcer, Ghana.
- genetics : Mycobacterium ulcerans.
- isolation & purification : Mycobacterium ulcerans.
- microbiology : Buruli Ulcer.
- physiology : Mycobacterium ulcerans.
- Adolescent, Adult, Child, Endemic Diseases, Female, Humans, Male, Young Adult.
Abstract
Mycobacterium ulcerans (MU) produces mycolactone toxin when infected with a plasmid. Toxin is cytotoxic and immunosuppressive, causing extensive destruction of tissues, leading to large ulcers on exposed parts of the body. Spontaneous healing by secondary intention leads to contractures, subluxation of joints, disuse atrophy, distal lymphedema and other complications. The disease is endemic in some communities within the middle belt of Ghana.
DOI: 10.1016/j.ijmyco.2015.03.006
PubMed: 26972882
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000944
Links to Exploration step
pubmed:26972882Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Mycobacterium ulcerans disease in the middle belt of Ghana: An eight-year review from six endemic districts.</title><author><name sortKey="Adu, Emmanuel J K" sort="Adu, Emmanuel J K" uniqKey="Adu E" first="Emmanuel J K" last="Adu">Emmanuel J K. Adu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. Electronic address: aduemmanuel@hotmail.com.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Department of Surgery, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi</wicri:regionArea></affiliation></author><author><name sortKey="Ampadu, Edwin" sort="Ampadu, Edwin" uniqKey="Ampadu E" first="Edwin" last="Ampadu">Edwin Ampadu</name><affiliation wicri:level="1"><nlm:affiliation>National Buruli Ulcer Control Programme, Korle Bu, Accra, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>National Buruli Ulcer Control Programme, Korle Bu, Accra</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26972882</idno><idno type="pmid">26972882</idno><idno type="doi">10.1016/j.ijmyco.2015.03.006</idno><idno type="wicri:Area/PubMed/Corpus">000944</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000944</idno><idno type="wicri:Area/PubMed/Curation">000944</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000944</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Mycobacterium ulcerans disease in the middle belt of Ghana: An eight-year review from six endemic districts.</title><author><name sortKey="Adu, Emmanuel J K" sort="Adu, Emmanuel J K" uniqKey="Adu E" first="Emmanuel J K" last="Adu">Emmanuel J K. Adu</name><affiliation wicri:level="1"><nlm:affiliation>Department of Surgery, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. Electronic address: aduemmanuel@hotmail.com.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>Department of Surgery, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi</wicri:regionArea></affiliation></author><author><name sortKey="Ampadu, Edwin" sort="Ampadu, Edwin" uniqKey="Ampadu E" first="Edwin" last="Ampadu">Edwin Ampadu</name><affiliation wicri:level="1"><nlm:affiliation>National Buruli Ulcer Control Programme, Korle Bu, Accra, Ghana.</nlm:affiliation><country xml:lang="fr">Ghana</country><wicri:regionArea>National Buruli Ulcer Control Programme, Korle Bu, Accra</wicri:regionArea></affiliation></author></analytic><series><title level="j">International journal of mycobacteriology</title><idno type="eISSN">2212-554X</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Anti-Bacterial Agents (administration & dosage)</term><term>Buruli Ulcer (drug therapy)</term><term>Buruli Ulcer (epidemiology)</term><term>Buruli Ulcer (microbiology)</term><term>Child</term><term>Endemic Diseases</term><term>Female</term><term>Ghana (epidemiology)</term><term>Humans</term><term>Male</term><term>Mycobacterium ulcerans (drug effects)</term><term>Mycobacterium ulcerans (genetics)</term><term>Mycobacterium ulcerans (isolation & purification)</term><term>Mycobacterium ulcerans (physiology)</term><term>Rifampin (administration & dosage)</term><term>Streptomycin (administration & dosage)</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Antibactériens (administration et posologie)</term><term>Enfant</term><term>Femelle</term><term>Ghana (épidémiologie)</term><term>Humains</term><term>Jeune adulte</term><term>Maladies endémiques</term><term>Mycobacterium ulcerans ()</term><term>Mycobacterium ulcerans (génétique)</term><term>Mycobacterium ulcerans (isolement et purification)</term><term>Mycobacterium ulcerans (physiologie)</term><term>Mâle</term><term>Rifampicine (administration et posologie)</term><term>Streptomycine (administration et posologie)</term><term>Ulcère de Buruli (microbiologie)</term><term>Ulcère de Buruli (traitement médicamenteux)</term><term>Ulcère de Buruli (épidémiologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Rifampin</term><term>Streptomycin</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Antibactériens</term><term>Rifampicine</term><term>Streptomycine</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Mycobacterium ulcerans</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Buruli Ulcer</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Buruli Ulcer</term><term>Ghana</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Mycobacterium ulcerans</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Mycobacterium ulcerans</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>Mycobacterium ulcerans</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Mycobacterium ulcerans</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Ulcère de Buruli</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Buruli Ulcer</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Mycobacterium ulcerans</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Mycobacterium ulcerans</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Ulcère de Buruli</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Ghana</term><term>Ulcère de Buruli</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Child</term><term>Endemic Diseases</term><term>Female</term><term>Humans</term><term>Male</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Enfant</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Maladies endémiques</term><term>Mycobacterium ulcerans</term><term>Mâle</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Mycobacterium ulcerans (MU) produces mycolactone toxin when infected with a plasmid. Toxin is cytotoxic and immunosuppressive, causing extensive destruction of tissues, leading to large ulcers on exposed parts of the body. Spontaneous healing by secondary intention leads to contractures, subluxation of joints, disuse atrophy, distal lymphedema and other complications. The disease is endemic in some communities within the middle belt of Ghana.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26972882</PMID><DateCreated><Year>2016</Year><Month>03</Month><Day>14</Day></DateCreated><DateCompleted><Year>2016</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2212-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>International journal of mycobacteriology</Title><ISOAbbreviation>Int J Mycobacteriol</ISOAbbreviation></Journal><ArticleTitle>Mycobacterium ulcerans disease in the middle belt of Ghana: An eight-year review from six endemic districts.</ArticleTitle><Pagination><MedlinePgn>138-42</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijmyco.2015.03.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2212-5531(15)00072-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Mycobacterium ulcerans (MU) produces mycolactone toxin when infected with a plasmid. Toxin is cytotoxic and immunosuppressive, causing extensive destruction of tissues, leading to large ulcers on exposed parts of the body. Spontaneous healing by secondary intention leads to contractures, subluxation of joints, disuse atrophy, distal lymphedema and other complications. The disease is endemic in some communities within the middle belt of Ghana.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To document the clinical and epidemiological features of MU disease in the middle belt of Ghana and the outcome of treatment.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Patients with lesions suspected to MU disease were screened by community workers. Lesions were confirmed by any of the following: direct smear examination, culture, polymerase chain reaction (PCR), or histopathology. Patients were treated with rifampicin (10mg/kg orally) and streptomycin (15 mg/kg IM) combination for eight weeks. Patients selected for surgical treatment included cases where medical treatment had failed, cases where medical treatment is contraindicated, cases presenting late with complications and recurrent cases.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">258 patients were seen in the Ahafo Ano, Amansie Central, Amansie West, Asunafo, Asutifi, and Upper Denkyira districts of Ghana between 2005 and 2012. Their ages ranged from 1 year 3 months to 98 years, with a mean age of 29.8 (SD 20.4). The clinical forms of MU disease seen were: papule (0.5%), nodule (1.5%), chronic osteomyelitis (1.5%), contracture (1.5%), edematous lesion (3%), and ulcer (92%). Uncommon complications include subluxation of knee joint, salivary gland fistula and Marjolin's ulcer. The lesions were distributed as follows: head and neck (6.8%), upper limb (20.3%), trunk (1.7%), and lower limb (71.2%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">MU disease in the middle belt of Ghana can be controlled by early case detection and adequate curative treatment.</AbstractText><CopyrightInformation>Copyright © 2015 Asian-African Society for Mycobacteriology. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adu</LastName><ForeName>Emmanuel J K</ForeName><Initials>EJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, School of Medical Sciences, Kwame Nkrumah University of Science and Technology, Kumasi, Ghana. Electronic address: aduemmanuel@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ampadu</LastName><ForeName>Edwin</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>National Buruli Ulcer Control Programme, Korle Bu, Accra, Ghana.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>04</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Mycobacteriol</MedlineTA><NlmUniqueID>101615660</NlmUniqueID><ISSNLinking>2212-5531</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>VJT6J7R4TR</RegistryNumber><NameOfSubstance UI="D012293">Rifampin</NameOfSubstance></Chemical><Chemical><RegistryNumber>Y45QSO73OB</RegistryNumber><NameOfSubstance UI="D013307">Streptomycin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054312" MajorTopicYN="N">Buruli Ulcer</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="Y">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019353" MajorTopicYN="N">Endemic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005869" MajorTopicYN="N">Ghana</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019911" MajorTopicYN="N">Mycobacterium ulcerans</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012293" MajorTopicYN="N">Rifampin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013307" MajorTopicYN="N">Streptomycin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibiotics</Keyword><Keyword MajorTopicYN="N">Contractures</Keyword><Keyword MajorTopicYN="N">Middle belt</Keyword><Keyword MajorTopicYN="N">Mycobacterium ulcerans</Keyword><Keyword MajorTopicYN="N">Skin grafting</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>03</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>03</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>03</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26972882</ArticleId><ArticleId IdType="pii">S2212-5531(15)00072-2</ArticleId><ArticleId IdType="doi">10.1016/j.ijmyco.2015.03.006</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000944 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000944 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:26972882
|texte= Mycobacterium ulcerans disease in the middle belt of Ghana: An eight-year review from six endemic districts.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:26972882" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |